<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010243</url>
  </required_header>
  <id_info>
    <org_study_id>MM03</org_study_id>
    <nct_id>NCT01010243</nct_id>
  </id_info>
  <brief_title>Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial</brief_title>
  <acronym>MM03</acronym>
  <official_title>Third-line Therapy of Multiple Myeloma With Lenalidomide in Combination With Pioglitazone, Dexamethasone and Metronomic Low-dose Chemotherapy With Treosulfan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of an anti-inflammatory therapy consisting of lenalidomide in&#xD;
      combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with&#xD;
      treosulfan on the response rate in patients with relapsed or refractory or progressive&#xD;
      multiple myeloma(MM).&#xD;
&#xD;
      Phase I: to determine the lenalidomide dse for the phase II part (5 mg or 10 mg or 15 mg) on&#xD;
      the basis of dose-limiting toxicities (DLTs') in the first 4 weeks of treatment.&#xD;
&#xD;
      Phase II: to determine&#xD;
&#xD;
        -  response rate (primary objective)&#xD;
&#xD;
        -  time to progression (TTP)&#xD;
&#xD;
        -  time to partial response (TPR)&#xD;
&#xD;
        -  overall survival (OS)&#xD;
&#xD;
        -  quality of life&#xD;
&#xD;
        -  tolerability and safety&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>2012</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>2012</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Pioglitazone, dexamethasone, treosulfan</intervention_name>
    <description>Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.&#xD;
Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Must be able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          -  Must be diagnosed with multiple myeloma that is progressing or has relapsed with&#xD;
             progressive disease after at least two different anti-myeloma treatments (including&#xD;
             lenalidomide in one schedule for phase II part only)&#xD;
&#xD;
          -  In case of patients that have progressive disease after complete remission during&#xD;
             preceding treatment: Serum monoclonal paraprotein (M-protein) level&#xD;
&#xD;
             ≥0.5 g/dL for IgG, IgA myeloma and ≥0.05 g/dL for IgD myeloma or urine M-protein level&#xD;
             ≥ 0.2 g excreted in a 24-hour collection sample or In case of progressive disease&#xD;
             without complete remission during preceding treatment: &gt; 25% increase of serum&#xD;
             monoclonal paraprotein or urine M-protein in comparison to the preceding monoclonal&#xD;
             paraprotein (M-protein)nadir in serum /urine M-protein nadir in a 24 hour collection&#xD;
             sample&#xD;
&#xD;
          -  Subjects must have been previously treated with lenalidomide for the phase II part.&#xD;
             Any first- and second-line treatment is allowed for the phase I part. Phase I study&#xD;
             inclusion independent of pre-treatment in 1st line.&#xD;
&#xD;
          -  Sufficient bone marrow function: neutrophils ≥ 2x109/l, hemoglobin ≥10 g/dl, and&#xD;
             platelets ≥ 100x109/l&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see&#xD;
             Post Text Supplement 2).&#xD;
&#xD;
          -  Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first&#xD;
             dose of study drug (at least 4 weeks).&#xD;
&#xD;
          -  Required laboratory results:&#xD;
&#xD;
               1. Liver function: Total bilirubin &lt; 1.5 times of upper limit of local institution&#xD;
                  (ULN), SGPT, SGOT ≤ 2.5 times of upper limit of local institution .&#xD;
&#xD;
               2. Renal function: serum creatinine ≤ 1.5 ULN c)PT-INR/PT &lt;1.5 ULN&#xD;
&#xD;
          -  Normal cardiac function&#xD;
&#xD;
          -  Patients with prior thromboembolic event with adequate anticoagulation&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Written informed consent of the patient prior to screening procedures&#xD;
&#xD;
          -  Patient must be available for treatment and follow-up&#xD;
&#xD;
          -  Any previous surgery must have taken place more than 4 weeks prior to inclusion&#xD;
&#xD;
          -  Previous radiation therapy must have involved less than 25% of bone marrow, and must&#xD;
             have been completed more than 4 weeks prior to inclusion.&#xD;
&#xD;
          -  Able to take acetylsalicylic acid (ASA) 100 mg daily as prophylactic anticoagulation&#xD;
             (patients intolerant to ASA may use low molecular weight heparin). Patients at high&#xD;
             risk for thromboembolic events should receive low molecular heparin. Patients with&#xD;
             history of thromboembolic event should pursue their ongoing anticoagulants (e.g.&#xD;
             phenprocoumon, warfarin, heparin) or receive another adequate prophylaxis, at least&#xD;
             LMWH).&#xD;
&#xD;
          -  Female subjects of childbearing potential† must:&#xD;
&#xD;
               -  Understand that the study medication has a teratogenic risk&#xD;
&#xD;
               -  Agree to use, and be able to comply with, effective contraception without&#xD;
                  interruption, 4 weeks before starting study drug, throughout study drug therapy&#xD;
                  (including dose interruptions) and for 4 weeks after the end of study drug&#xD;
                  therapy, even if she has amenorrhoea.This applies unless the subject commits to&#xD;
                  absolute and continued abstinence confirmed on a monthly basis. The following are&#xD;
                  effective methods of contraception*&#xD;
&#xD;
          -  Implant**&#xD;
&#xD;
          -  Levonorgestrel-releasing intrauterine system (IUS)**&#xD;
&#xD;
          -  Medroxyprogesterone acetate depot&#xD;
&#xD;
          -  Tubal sterilization&#xD;
&#xD;
          -  Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed&#xD;
             by two negative semen analyses&#xD;
&#xD;
          -  Ovulation inhibitory progesterone-only pills (i.e., desogestrel)&#xD;
&#xD;
               -  Because of the increased risk of venous thromboembolism in patients with multiple&#xD;
                  myeloma, combined oral contraceptive pills are not recommended. If a subject was&#xD;
                  using combined oral contraception, she must switch to one of the methods above.&#xD;
                  The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral&#xD;
                  contraception.&#xD;
&#xD;
                    -  prophylactic antibiotics should be considered at the time of insertion&#xD;
                       particularly in patients with neutropenia due to risk of infection&#xD;
&#xD;
          -  Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25&#xD;
             mIU/ml not more than 3 days from the start of study medication once the subject has&#xD;
             been on effective contraception for at least 4 weeks. This requirement also applies to&#xD;
             women of childbearing potential who practice complete and continued abstinence.&#xD;
&#xD;
          -  Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks&#xD;
             after the end of study treatment, except in the case of confirmed tubal sterilization.&#xD;
             These tests should be performed not more than 3 days before the start of next&#xD;
             treatment. This requirement also applies to women of childbearing potential who&#xD;
             practice complete and continued abstinence&#xD;
&#xD;
          -  Male subjects must&#xD;
&#xD;
               -  Agree to use condoms throughout study drug therapy, during any dose interruption&#xD;
                  and for one week after cessation of study therapy if their partner is pregnant or&#xD;
                  is of childbearing potential and has no contraception.&#xD;
&#xD;
               -  Agree not to donate semen during study drug therapy and for one week after end of&#xD;
                  study drug therapy.&#xD;
&#xD;
          -  All subjects must&#xD;
&#xD;
               -  Agree to abstain from donating blood while taking study drug therapy and for one&#xD;
                  week following discontinuation of study drug therapy.&#xD;
&#xD;
               -  Agree not to share study medication with another person and to return all unused&#xD;
                  study drug to the investigator † A female subject or a female partner of a male&#xD;
                  subject is considered to have childbearing potential unless she meets at least&#xD;
                  one of the following criteria: Age ≥50 years and naturally amenorrhoeic for ≥ 1&#xD;
                  year (amenorrhoea following cancer therapy does not rule out childbearing&#xD;
                  potential), premature ovarian failure confirmed by a specialist gynaecologist,&#xD;
                  previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner's&#xD;
                  syndrome or uterine agenesis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who require vitamin K antagonists except for low dose (INR ≤ 2,5)&#xD;
&#xD;
          -  Known hypersensitivity to dexamethasone. Prior history of uncontrollable side effects&#xD;
             to dexamethasone therapy.&#xD;
&#xD;
          -  Active infection &gt; grade 2 NCI-CTC version 3.0&#xD;
&#xD;
          -  Known diagnosis of HIV, hepatitis B, or hepatitis C infection.&#xD;
&#xD;
          -  Severe, unstable, or uncontrolled medical disease which would confound diagnoses or&#xD;
             evaluations required by the protocol, including cardiac insufficiency (NYHA I -IV)&#xD;
             uncontrolled diabetes, chronic hepatic or renal disease, active uncontrolled infection&#xD;
             and chronic inflammatory intestinal disease, autoimmune diseases.&#xD;
&#xD;
          -  Prior radiation therapy &gt; 25% of bone marrow&#xD;
&#xD;
          -  Regular blood transfusions&#xD;
&#xD;
          -  Treatment with other experimental substances within 30 days before study start&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days before study start or during&#xD;
             the trial&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Patients with seizure disorders requiring medication (such as steroids or&#xD;
             antiepileptics)&#xD;
&#xD;
          -  Known hypersensitivity to one of the medications&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
          -  Patients undergoing renal dialysis&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to start of study or incomplete wound healing&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Psychological or social conditions that may interfere with the patients participation&#xD;
             in the study or evaluation of the study results&#xD;
&#xD;
          -  Known (at time of entry) gastrointestinal disorder, including malabsorption or active&#xD;
             gastric ulcer, present to the extent that it might interfere with oral intake and&#xD;
             absorption of study medication&#xD;
&#xD;
          -  Any previous or concurrent malignancy or any cancer unless curatively treated &gt; 3&#xD;
             years prior to study entry except cervical carcinoma in situ or adequately treated&#xD;
             basal cell carcinoma&#xD;
&#xD;
          -  Neuropathy &gt; Grade 2&#xD;
&#xD;
          -  Patients with bladder cancer or bladder cancer in their medical history&#xD;
&#xD;
          -  Macrohematuria of unknown origin&#xD;
&#xD;
          -  Patients with risk factors for bladder cancer (such as exposure to aromatic amines or&#xD;
             heavy tobacco smokers)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albrecht Reichle, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albrecht Reichle, Professor MD</last_name>
    <phone>+499419445540</phone>
    <email>albrecht.reichle@klinik.uni-regensburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Schön Klinik Starnberger See</name>
      <address>
        <city>Berg</city>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Straka, PD MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Straka, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. med. J. Wilke u. H. Wagner</name>
      <address>
        <city>Fürth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Wilke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jochen Wilke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, II Medizin, Sekt. f. Stammzell- u. Immuntherapie</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gramatzki, Prof. MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Gramatzki, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum d. Universität München, Med. Klinik u. Poliklinik IV, Abt. H/O</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Adam, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Adam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Hämato/Onkologie</name>
      <address>
        <city>München</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Schmidt, MD</last_name>
    </contact>
    <investigator>
      <last_name>Burkhard Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Reichle, Professor</last_name>
      <email>albrecht.reichle@klinik.uni-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Grube, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joachim Hahn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Mayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Vogelhuber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Hart, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin Landfried, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Petronio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dagmar Roll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Zilch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2009</study_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Albrecht Reichle</investigator_full_name>
    <investigator_title>Professor MD</investigator_title>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>progressive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

